Pfizer: Carcinoma, Hepatocellular trials
The registry lists 12 Carcinoma, Hepatocellular studies with Pfizer as lead sponsor. 2 are open to participants now and 7 have results posted.
Phase 1 7Phase 2 4Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingNCT07227012Phase 1/2
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
- A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)CompletedNCT03289533Phase 1Results posted
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedNCT02315066Phase 1Results posted
- A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver CancerTerminatedNCT01911273Phase 2Results posted
- Asian Phase I Study Of PF-03446962CompletedNCT01337050Phase 1Results posted
- Axitinib For The Treatment Of Advanced Hepatocellular CarcinomaCompletedNCT01210495Phase 2Results posted
- Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver CancerTerminatedNCT00699374Phase 3Results posted
- A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.CompletedNCT00428220Not applicableResults posted
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedNCT04458259Phase 1
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.WithdrawnNCT01441388Phase 1
- Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular CarcinomaCompletedNCT00635323Phase 2